Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

Dominick J. Angiolillo, Jayne Prats, Efthymios N. Deliargyris, David J. Schneider, James Scheiman, Carey Kimmelstiel, Ph Gabriel Steg, Mark Alberts, Todd Rosengart, Roxana Mehran, Deepak L. Bhatt

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Aspirin is one of the most widely used medicines. Although aspirin is commonly utilized for the treatment of several medical conditions, its broadest uptake is for the prevention of recurrent ischemic events in patients with atherosclerotic disease. Its mechanism of action of inhibiting platelet activation via blockade of thromboxane A2 production is unique and is not covered by any other antiplatelet agents. While plain, uncoated, immediate-release aspirin is used in acute settings to help assure rapid absorption, enteric-coated aspirin formulations dominate current chronic use, particularly in North America, including for secondary prevention of cardiovascular events. The unmet needs with current aspirin formulations include a high risk of gastrointestinal (GI) adverse events with plain aspirin, which enteric-coated formulations are not able to overcome, and subject to erratic absorption leading to reduced drug bioavailability. These observations underscore the need for aspirin formulations with a more favorable safety and efficacy profile. Phospholipid-aspirin complex (PL-ASA) is a novel formulation designed to address these needs. It is associated with reduced local acute GI injury compared with plain aspirin, and predictable absorption resulting in more reliable platelet inhibition compared with enteric-coated tablets. This review explores the rationale and pharmacologic profile of PL-ASA intended to address the unmet needs for aspirin therapy.

Original languageEnglish
Pages (from-to)465-479
Number of pages15
JournalClinical Pharmacokinetics
Issue number4
StatePublished - Apr 2022


Dive into the research topics of 'Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation'. Together they form a unique fingerprint.

Cite this